A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001 - APX001 Safety, PK, Bioavailability, FE, DDI Study

Amplyx Pharmaceuticals, Inc.0 sites46 target enrollmentTBD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: Amplyx Pharmaceuticals, Inc.
Enrollment: 46
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Amplyx Pharmaceuticals, Inc.

Eligibility Criteria

Inclusion Criteria

•Healthy male or female subjects
•Age 18 to 55 years, inclusive
•Body mass index (BMI) between 18\.0 and 30\.0 kg/m2, inclusive.

Exclusion Criteria

•Suffering from cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric diseases, or neoplastic disorder with metastatic potential. Participation in a drug study within 60 days prior to (the first) drug administration in the current study. Pregnancy. Suffering from hepatitis B, hepatitis C, HIV/AIDS.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

A phase 1, randomized, placebo-controlled study to assess the safety and pharmacokinetics of multiple ascending dose regimens of TP-6076.Infecties.Infections.

NL-OMON45496Tetraphase Pharmaceuticals, Inc.56

Completed

Phase 1

A trial of BIT225 in patients with HIV-1 infection, to study the safety, concentration and distribution in the body, and anti-viral activity of the drug.

ACTRN12612000696897Biotron Limited24

Recruiting

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of PLX-4545 in Healthy VolunteersSolid TumoursCancer - Any cancer

ACTRN12623001265662Plexium Australia Pty Ltd96

Recruiting

Phase 1

A Study to Evaluate the Safety of a Single and Multiple Oral Doses of a Biologic Therapy (MB-001) or placebo in Healthy Human Participantslcerative colitisUlcerative colitisOral and Gastrointestinal - Inflammatory bowel disease

ACTRN12624000524594Mage Biologics48

Not yet recruiting

Phase 4

Clinical Study to Evaluate the Efficacy and Safety in Healthy Adults for a period of 2 months for the safety endpoints.

CTRI/2024/05/066815Herbal Creations